cladribine and plx4032
cladribine has been researched along with plx4032 in 12 studies
Research
Studies (12)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Acker, T; Andrulis, M; Blume, C; Capper, D; Dietrich, S; Fröhling, S; Garvalov, BK; Glimm, H; Ho, AD; Hüllein, J; Hundemer, M; Jethwa, A; Lehners, N; Mandel, T; Meissner, J; Schulte, C; von Kalle, C; Zenz, T | 1 |
| Manevich-Mazor, M; Mazor, RD; Shoenfeld, Y | 1 |
| Jain, P; Pemmaraju, N; Ravandi, F | 1 |
| Aizenstein, O; Eshed, I; Ganzel, C; Goldberg, I; Gural, A; Jaffe, R; Kesler, A; Manevich-Mazor, M; Mazor, RD; Pessach, Y; Shoenfeld, Y; Sprecher, E; Yaish, I | 1 |
| Abdel-Wahab, O; Salam, L | 1 |
| Dearden, C | 1 |
| Andritsos, LA; Grever, MR | 1 |
| Catovsky, D; Dearden, CE; Else, M | 1 |
| Getta, BM; Park, JH; Tallman, MS | 1 |
| Andrasiak, I; Rybka, J; Wrobel, T | 1 |
| Baidildina, D; Bronin, G; Burtsev, E; Cherniak, E; Dzhukaeva, I; Erega, E; Evseev, D; Fink, O; Ignatova, A; Kalinina, I; Kotskaya, N; Litvin, E; Lyudovskikh, E; Maschan, A; Maschan, M; Novichkova, G; Osipova, D; Popov, A; Pristanskova, E; Purbueva, B; Raykina, E; Semchenkova, A; Vlasova, I; Voronin, K; Zhogov, V | 1 |
Reviews
7 review(s) available for cladribine and plx4032
| Article | Year |
|---|---|
Erdheim-Chester Disease: a comprehensive review of the literature.
Topics: Cladribine; Erdheim-Chester Disease; Humans; Indoles; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Sulfonamides; Vemurafenib | 2013 |
Update on the biology and treatment options for hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease-Free Survival; Humans; Immunophenotyping; Immunotoxins; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Recombinant Proteins; Recurrence; Rituximab; Sulfonamides; Vemurafenib | 2014 |
Hairy cell leukemia: update and current therapeutic approach.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Clinical Trials as Topic; Gene Expression; Humans; Imidazoles; Indoles; Leukemia, Hairy Cell; Mutation; Oximes; Pentostatin; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Sulfonamides; Vemurafenib | 2015 |
Historical overview of hairy cell leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease Management; History, 20th Century; History, 21st Century; Humans; Immunotoxins; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Remission Induction; Rituximab; Splenectomy; Sulfonamides; Survival Analysis; Vemurafenib | 2015 |
Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Follow-Up Studies; Humans; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Prognosis; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Rituximab; Sulfonamides; Survival Analysis; Vemurafenib | 2015 |
Hairy cell leukemia: Past, present and future.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease Management; History, 20th Century; History, 21st Century; Humans; Immunotoxins; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Remission Induction; Rituximab; Splenectomy; Sulfonamides; Survival Analysis; Vemurafenib | 2015 |
Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Treatment Outcome; Vemurafenib | 2018 |
Other Studies
5 other study(ies) available for cladribine and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Drug Resistance, Neoplasm; Flow Cytometry; Glutamic Acid; Humans; Indoles; Induction Chemotherapy; Leukemia, Hairy Cell; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Proto-Oncogene Proteins B-raf; Rituximab; Sulfonamides; Treatment Outcome; Valine; Vemurafenib | 2013 |
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Biopsy; Cladribine; Erdheim-Chester Disease; Female; Humans; Indoles; Infliximab; Interferons; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2014 |
Hairy cell leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease Management; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Leukemia, Hairy Cell; Male; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Sex Factors; Sulfonamides; Vemurafenib | 2015 |
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Vemurafenib | 2023 |